ADULT MESENCHYMAL STEM CELLS FOR ORTHOPEDICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Global Adult Mesenchymal Stem Cells for Orthopedics Market Size and Forecast – 2026 To 2033

The global adult mesenchymal stem cells for orthopedics market is expected to grow from USD 195.0 Mn in 2026 to USD 382.3 Mn by 2033, registering a compound annual growth rate (CAGR) of 10.1% from 2026 to 2033. The market for adult mesenchymal stem cells for orthopedics is poised for significant expansion, fueled by the soaring burden of osteoarthritis, which is one of the leading causes of disability globally.

According to the Osteoarthritis Action Alliance, approximately 242 million people globally have symptomatic and activity-limiting osteoarthritis of the hip and/or knee, highlighting the growing need for regenerative therapies such as mesenchymal stem cell-based treatments.

Key Takeaways of the Global Adult Mesenchymal Stem Cells for Orthopedics Market

• Bone marrow is projected to hold 71.0% of the global adult mesenchymal stem cells for orthopedics market share in 2026, making it the dominant source segment across North America due to its extensive clinical validation, standardized harvesting procedures, and widespread use in orthopedic regenerative research. For instance, the U.S. Food and Drug Administration (FDA) has established a comprehensive regulatory framework for regenerative medicine products, including human cell and tissue-based products (HCT/Ps), providing guidance on manufacturing, safety, and clinical development to facilitate the translation of cell-based orthopedic therapies.
• Knee injuries are projected to hold 57.6% of the global adult mesenchymal stem cells for orthopedics market share in 2026, making it the dominant application segment across Asia Pacific due to the high prevalence of knee osteoarthritis, increasing elderly population, and supportive regenerative medicine regulations. For instance, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) publishes Optimal Use Guidelines for Regenerative Medicine Products, outlining requirements for healthcare institutions, patient selection, and post-marketing use to ensure the safe clinical application of regenerative therapies.
• Hospitals are projected to hold 49.2% of the global adult mesenchymal stem cells for orthopedics market share in 2026, making it the dominant end user segment across Europe due to the availability of specialized orthopedic centers, advanced surgical infrastructure, and regulated administration of cell-based therapies. For instance, the European Medicines Agency (EMA) evaluates cell-based regenerative therapies under the Advanced Therapy Medicinal Products (ATMP) regulatory framework, requiring these therapies to meet stringent quality, safety, and efficacy standards before clinical use in specialized healthcare settings.
• North America maintains its dominance with an estimated share of 33.8% in 2026, bolstered by a mature regenerative medicine ecosystem, robust clinical research infrastructure, and supportive regulatory pathways. For instance, in September 2024, the U.S. Food and Drug Administration (FDA) published an updated guidance on Considerations for the Demonstration of Comparability of Human Cellular and Gene Therapy Products, providing clearer regulatory expectations for manufacturing changes and facilitating the clinical development of regenerative medicine products, including cell therapies.
• Asia Pacific is expected to exhibit the fastest growth with an estimated contribution of 20.3% share in 2026, driven by expanding regenerative medicine infrastructure, increasing orthopedic disease burden, and supportive government regulations. For instance, in March 2024, Japan's Ministry of Health, Labour and Welfare (MHLW) revised the Implementation Procedures for the Act on the Safety of Regenerative Medicine, strengthening oversight of regenerative medicine practices while supporting their safe clinical adoption.
• Increasing adoption of MSCs for intervertebral disc degeneration (IVDD) and cartilage regeneration: Growing clinical evidence supporting the use of mesenchymal stem cells (MSCs) for intervertebral disc degeneration and articular cartilage repair is expanding their application beyond osteoarthritis. Their ability to modulate inflammation and promote tissue regeneration is improving treatment outcomes while reducing the need for invasive orthopedic surgeries. This is encouraging greater investment in clinical research and accelerating market adoption.
• Integration of MSCs with biomaterials and 3D bioprinting for orthopedic tissue engineering: The convergence of MSC therapy with bioengineered scaffolds, hydrogels, and 3D bioprinting technologies is creating next-generation regenerative solutions for complex bone and cartilage defects. These combination approaches enhance cell survival, targeted tissue regeneration, and structural support, expanding the therapeutic potential of MSC-based orthopedic treatments. Continued innovation in tissue engineering is expected to unlock new commercial opportunities across personalized regenerative medicine.

Segmental Insights 

To learn more about this report, Request Free Sample

Why Does Bone Marrow Dominate the Global Adult Mesenchymal Stem Cells for Orthopedics Market?

Bone marrow is projected to hold a market share of 71.0% in 2026, due to established regenerative efficacy, optimized osteogenic and chondrogenic differentiation potential, along with significant and repeated successful clinical trials in orthopedic regenerative therapies. The continued clinical endorsement and established mesenchymal stem cells harvesting protocols support its widespread adoption in orthopedic regenerative medicine. For instance, in October 2024, a clinical results of RESPINE multicenter, randomized, placebo-controlled trial, were published by National Library of Medicine, providing clinical assessment of the allogeneic bone marrow-derived mesenchymal stromal cell therapy for chronic low back pain patients, further reinforcing the therapeutic potential of bone marrow-derived MSCs in orthopedic applications.

Why Do Knee Injuries Represent the Largest Application Segment in the Adult Mesenchymal Stem Cells for Orthopedics Market? 

To learn more about this report, Request Free Sample

Knee injuries are projected to hold a market share of 57.6% in 2026, due to high incidence of knee osteoarthritis, cartilage defects and sports injuries as well as inclination towards regenerative treatments in order to maintain joint function and delay hip and knee Replacement. Mesenchymal stem cell (MSC)-targeted interventions have rapidly become the primary therapeutic approach due to their capabilities of cartilage regeneration and reduce inflammation with relatively minimum invasive procedure. For instance, In December 2025, Cipla entered into an agreement with Stempeutics Research to launch Ciplostem – a Drugs Controller General of India (DCGI)-approved allogeneic bone marrow-derived mesenchymal stem cell therapy for knee osteoarthritis Grades II and III.

Hospitals Segment Dominates the Global Adult Mesenchymal Stem Cells for Orthopedics Market

The hospitals segment is projected to hold a market share of 49.2% in 2026, due to the necessity of the integrated infrastructure consisting of orthopedic surgical suite, diagnostic imaging, cell processing, and rehabilitative services required for the safest application for adult MSCs to treat orthopedic patients. Their participation in regenerative medicine programs and clinical trials further hastened the adoption of MSC-based therapeutic approaches within orthopedics. For instance, in January 2025, Cedars-Sinai expanded the Cedars-Sinai Regenerative Ortho biologic Center, unifying a multidisciplinary group of hip-preservation orthopedic surgeons and regenerative medicine scientists with the goal of researching, treating and generating stem cell–derived therapeutic treatments for common orthopedic injuries, underscoring hospitals central role in innovative breakthroughs in regenerative orthopedics.

Current Events and their Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Global Adult Mesenchymal Stem Cells for Orthopedics Market Dynamics

To learn more about this report, Request Free Sample

Market Drivers

Rising prevalence of osteoarthritis and musculoskeletal disorders

The increasing burden of osteoarthritis and other degenerative musculoskeletal disorders is driving the demand for regenerative orthopedic therapies, including adult mesenchymal stem cells (MSCs). Their ability to promote cartilage repair, reduce inflammation, and support tissue regeneration positions MSCs as a promising alternative to conventional symptomatic treatments. For instance, the Global Burden of Disease (GBD) 2021 study estimated that approximately 607 million people worldwide were living with osteoarthritis in 2021, with the disease burden projected to continue rising through 2050, reinforcing the long-term need for advanced regenerative therapies.

Growing demand for regenerative alternatives to joint replacement

The growing preference for minimally invasive regenerative therapies over conventional joint replacement procedures is driving the adoption of adult mesenchymal stem cells (MSCs) in orthopedics. MSC-based therapies offer the potential to repair damaged cartilage, reduce inflammation, and delay or even avoid the need for total joint replacement, particularly among younger and active patients. For instance, in June 2025, the UK's National Institute for Health and Care Excellence (NICE) updated its guidance on osteoarthritis management, emphasizing early non-surgical interventions and individualized treatment pathways before considering joint replacement surgery, supporting interest in regenerative treatment approaches.

Emerging Trends

Growing Adoption of AI-Enabled Cell Manufacturing and Quality Control

Artificial intelligence and digital analytics are increasingly being integrated into mesenchymal stem cell manufacturing to optimize cell expansion, automate quality control, and improve batch consistency. These technologies are expected to enhance production efficiency while reducing manufacturing variability and costs.

Shift Toward Personalized MSC Therapies with Biomarker-Guided Patient Selection

Advancements in precision medicine are driving the use of biomarker-based patient stratification to identify individuals most likely to respond to MSC therapy. This personalized treatment approach is improving clinical outcomes, supporting evidence-based therapy selection, and accelerating the adoption of regenerative medicine in orthopedics.

Regional Insights

To learn more about this report, Request Free Sample

Why is North America a Strong Market for Adult Mesenchymal Stem Cells for Orthopedics?

North America leads the global adult mesenchymal stem cells for orthopedics market, accounting for an estimated 33.8% share in 2026, driven by favorable healthcare ecosystem, fertile grounds for regenerative medicine research and active biopharmaceutical companies working on the development and commercialization of orthopedics-targeted stem cells product. A well-established landscape for clinical trials and a faster implementation of MSC-based approaches into clinical settings characterizes the market. Additionally, streamlined approval processes by the U.S. FDA have expedited regulatory approval for regenerative medicine, driving the development and clinical integration of cell-based orthopedic treatments and facilitating other cell therapies and applications.

For instance, the U.S. Food and Drug Administration (FDA) has established the Regenerative Medicine Advanced Therapy (RMAT) designation process under the 21st Century Cures Act – a pathway that allows for intensive FDA monitoring, development planning and priority FDA review of eligible regenerative medicine products, accelerating the development of MSC therapies for orthopedic care.

Why Does the Asia Pacific Adult Mesenchymal Stem Cells for Orthopedics Market Exhibit High Growth?

The Asia Pacific adult mesenchymal stem cells for orthopedics market is expected to exhibit the fastest growth with an estimated contribution of 20.3% share to the global market in 2026, owing to its rapidly growing healthcare infrastructure, surging demand for regenerative medicine, and expansion of biopharmaceutical industries. The proliferation of government initiatives from encouraging research on biotechnology and regenerative medicine further accelerate these therapies’ clinical validation, which is subsequently leading towards the growth of the market.

For instance, under China's 14th Five-Year Bioeconomy Development Plan, the government classified biomedicine as one of its strategic industries to boost the use of innovative biomedical technology and its clinical applications. The innovation project is supporting development of a stronger ecosystem for stem cell-based treatments and their broader clinical adoption. (Source: United Nations Environment Programme) Moreover, favorable regulatory environment, competitive manufacturing costs, and stringent adherence to standards help the regions to get recognized as a core center for orthopedic regenerative therapies.

Global Adult Mesenchymal Stem Cells for Orthopedics Market Outlook for Key Countries

Why is the U.S. Leading Innovation and Adoption in the Adult Mesenchymal Stem Cells for Orthopedics Market?

The U.S. dominates the adult mesenchymal stem cells for orthopedics market led by the most sophisticated regenerative medicine ecosystem of specialized cell therapy developers (such as Mesoblast Limited and Vericel Corporation), premier orthopedic centers (such as Hospital for Special Surgery and Mayo Clinic), and research & translational institutes (such as the Mayo Clinic Center for Regenerative Biotherapeutics and the Wake Forest Institute for Regenerative Medicine). The country holds a leading position with developed capabilities in GMP (Good Manufacturing Practice) certified MSC manufacturing and premature inclusion of cell-based solutions within orthopedic clinics for enhanced development and acceptance of orthopedic regenerations remedies.

Is Japan a Favorable Market for Adult Mesenchymal Stem Cells for Orthopedics Market?

Japan is one of the most promising markets for the adult mesenchymal stem cells for orthopedics, based on the country’s expertise in regenerative medicine and its well-established reputation and infrastructure for the advancement of cartilage repair and joint-preserving therapies. Japan has a well-developed clinical ecosystem for cell therapy-based orthopedic treatments supported by highly knowledgeable regenerative medicine companies and state-of-the-art cell manufacturing facilities for a quick transition to the clinical setting.

Is China Emerging as a Key Growth Hub for the Adult Mesenchymal Stem Cells for Orthopedics Market?

China is positioned as a key growth hub in the global adult mesenchymal stem cells for orthopedics market due to its improving generative medicines facility manufacturing infrastructure and adoption of new cell therapy systems commercially. The country boasts an impressive robust ecosystem which includes biotechnology companies (such as Beike Biotechnology and Vcanbio Cell & Gene Engineering Corporation), GMP-compliant cell manufacturing facilities (such as Shanghai Cell Therapy Group and Boyalife Group), and orthopedic research hospitals (such as Peking University Third Hospital and Shanghai Sixth People's Hospital) enabling rapid development of and translation into clinical settings of large numbers of therapeutic cell treatments.

Why Does Germany Top the European Adult Mesenchymal Stem Cells for Orthopedics Market?

Germany leads the European adult mesenchymal stem cells for orthopedics market attributed to its immense capacity in tissue engineered cartilage, cell manufacturing process, and translational research in orthopedics. The country has a good record in both autologous and allogeneic stem cell based regenerative products with proven manufacturing capabilities of cellular based products according to European GMP standards and integration into existing practice in orthopedic clinics.

Is Adult Mesenchymal Stem Cells for Orthopedics Market Developing in India?

India is a high-potential market for adult mesenchymal stem cells for orthopedics due to rising domestic expertise, coupled with increased commercial success for native cell-based therapies to accelerate further. The rising focus toward GMP-certified cell manufacturing, improved orthopedic translational R&D, and increasing availability of cost-effective MSC therapies that aim to support cartilage repair and musculoskeletal problems are expected to support the growth for the country.

Product Innovation Landscape in the Global Adult Mesenchymal Stem Cells for Orthopedics Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

How are the expanding clinical trials for orthopedic MSC therapies creating new growth opportunities in the adult mesenchymal stem cells for orthopedics market?

The growing interest in clinical studies involving mesenchymal stem cells (MSCs) for orthopedic uses is boosting the clinical data that support their safety and effectiveness. Favorable trial results will likely encourage regulatory approvals, improve physician confidence and hasten wider acceptance of regenerative therapies to promote cartilage repair and to manage osteoarthritis. For instance, in march 2022, phase III multicenter randomized double-blind placebo-controlled study (clinicaltrials.gov identifier: nct05288725) was registered on ClinicalTrials.gov for assessing the efficacy and safety of mesenchymal stem cell therapy for knee osteoarthritis, indicating the ongoing progress in late phase clinical development of orthopedic treatments relying on mesenchymal stem cell therapy.

Market Players, Key Development, and Competitive Intelligence

To learn more about this report, Request Free Sample

Key Developments

• On July 7, 2026, MEDIPOST announced that the first U.S. participant had been treated in its Phase III clinical trial evaluating Cartistem, an allogeneic umbilical cord blood-derived stem cell therapy for symptomatic cartilage defects caused by knee osteoarthritis. The milestone expands the therapy's late-stage clinical evaluation in the U.S. and reinforces the growing adoption of regenerative cell therapies for orthopedic applications.
• In January 2026, Cytora Therapeutics entered into a strategic partnership with Made Scientific and Zeo ScientiFiX to manufacture and commercialize its allogeneic stem cell therapy in the U.S. The collaboration aims to accelerate clinical development, manufacturing scale-up, and commercialization of regenerative cell therapies, supporting broader adoption of advanced stem cell-based treatments for orthopedic applications.

Competitive Landscape

The global adult mesenchymal stem cells for orthopedics market moderately consolidated, with competition centered on clinical efficacy, regulatory compliance, manufacturing scalability, and product standardization. Companies are focusing on expanding allogeneic and autologous MSC portfolios, strengthening clinical evidence through late-stage trials, and enhancing GMP-compliant manufacturing capabilities to support commercialization. Strategic collaborations with research institutes, hospitals, and contract development and manufacturing organizations (CDMOs), along with geographic expansion into high-growth markets, are further intensifying competition. Key focus areas include:

• Advancement of allogeneic, off-the-shelf MSC therapies
• Expansion of late-stage clinical trials
• Investment in GMP-compliant manufacturing and automated cell processing
• Strategic collaborations with hospitals, academic institutions, and CDMOs
• Geographic expansion and regulatory approvals in high-growth markets

Market Report Scope

Analyst Opinion (Expert Opinion)

• In the coming years, the global adult mesenchymal stem cells for orthopedics market is expected to transition from a predominantly research-driven landscape to a commercialization-focused market over the next decade, supported by growing clinical validation, regulatory advancements, and increasing physician acceptance of regenerative therapies. As evidence continues to demonstrate the long-term benefits of mesenchymal stem cells -based treatments, these therapies are likely to become an integral part of orthopedic care, particularly for degenerative musculoskeletal disorders.
• The maximum opportunities will probably exist within knee osteoarthritis applications across Asia Pacific, particularly Japan and South Korea, where a rapidly aging population, high osteoarthritis prevalence, and progressive regenerative medicine regulations are accelerating the adoption of cell-based therapies. These countries are expected to remain key hubs for clinical innovation and commercialization of orthopedic mesenchymal stem cells products.
• In order to obtain a competitive advantage, market participants should prioritize late-stage clinical validation, investment in scalable GMP-compliant manufacturing, and the development of cost-effective allogeneic mesenchymal stem cells platforms. Strategic collaborations with hospitals, academic research institutions, and contract manufacturing organizations, coupled with early engagement with regulatory agencies and expansion into high-growth Asia-Pacific markets, will be critical for strengthening market position and accelerating commercialization

Market Segmentation

• Source Insights (Revenue, USD Mn, 2021 - 2033)
  • Bone Marrow
  • Adipose Tissue
• Application Insights (Revenue, USD Mn, 2021 - 2033)
  • Knee Injuries
  • Shoulder Injuries
  • Ankle Injuries
  • Foot Injuries
  • Back and Spine Injuries
  • Others
• End User Insights (Revenue, USD Mn, 2021 - 2033)
  • Hospitals
  • Specialty Clinics
  • Academic and Research Institutions
  • Others
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa

Sources

Primary Research Interviews

• Orthopedic surgeons specializing in regenerative medicine and cartilage restoration
• Stem cell therapy clinicians and musculoskeletal medicine specialists
• Cell therapy manufacturing and GMP quality assurance professionals
• Executives and product managers from mesenchymal stem cell therapy companies
• Clinical research organizations (CROs) involved in orthopedic stem cell trials

Stakeholders

• Adult mesenchymal stem cell therapy manufacturers
• Cell therapy contract development and manufacturing organizations (CDMOs)
• Hospitals and orthopedic specialty clinics
• Academic and regenerative medicine research institutes
• End-use Sectors
  • Hospitals
  • Orthopedic specialty centers
  • Ambulatory surgery centers (ASCs)
  • Regenerative medicine clinics
  • Research and academic institutes
• Regulatory & Health Bodies
  • U.S. Food and Drug Administration (FDA)
  • European Medicines Agency (EMA)
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Ministry of Food and Drug Safety (MFDS), South Korea
  • National Medical Products Administration (NMPA), China
  • Health Canada
  • Therapeutic Goods Administration (TGA), Australia

Databases

• ClinicalTrials.gov
• FDA Cellular & Gene Therapy Guidances Database
• EMA Advanced Therapy Medicinal Products (ATMP) Database
• WHO Global Health Observatory (GHO)
• NIH Stem Cell Information Portal

Magazines

• RegMedNet
• Cell & Gene Therapy Review
• Genetic Engineering & Biotechnology News (GEN)
• BioProcess International
• The Medicine Maker

Journals

• Stem Cells Translational Medicine
• Journal of Orthopaedic Research
• Journal of Orthopaedic Translation
• Cytotherapy
• Regenerative Medicine
• Nature Reviews Rheumatology

Newspapers

• The Wall Street Journal
• Financial Times
• USA Today
• The New York Times

Associations

• International Society for Cell & Gene Therapy
• Orthopaedic Research Society
• American Academy of Orthopaedic Surgeons
• International Cartilage Regeneration & Joint Preservation Society
• Tissue Engineering and Regenerative Medicine International Society

Public Domain Sources

• World Health Organization – Musculoskeletal Health & Global Health Observatory
• U.S. Food and Drug Administration – Cellular & Gene Therapy / Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)
• European Medicines Agency – Advanced Therapy Medicinal Products (ATMPs)
• National Institutes of Health – Stem Cell Information & Regenerative Medicine Research
• ClinicalTrials.gov – Orthopedic MSC Clinical Trial Registry
• Organisation for Economic Co-operation and Development – Health Statistics
• World Bank – Health Expenditure & Demographic Indicators

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 10 years.